Chronic Lymphocytic Leukemia | Specialty

CLL Research Explores Feasibility of Time-Limited Treatment

February 22nd 2019

Nicole Lamanna, MD, highlights the latest MURANO data in CLL, delving into the need for more studies to test the feasibility of time-limited treatment in this patient population.

Ibrutinib Plus CAR T-Cell Therapy Boosts Response in CLL

February 22nd 2019

Patients with relapsed/refractory chronic lymphocytic leukemia had an improved response rate with chimeric antigen receptor T-cell therapy if they also received ibrutinib.

Novel CLL Regimens Show Promising Efficacy

February 20th 2019

Suman Kambhampati, MD, reflects on the emergence of data in chronic lymphocytic leukemia from the 2018 ASH Annual Meeting.

Ibrutinib/JCAR014 Combo Shows Potential in Relapsed/Refractory CLL

February 13th 2019

Jordan Gauthier, MD, MSc, discusses retrospective results of concurrent ibrutinib and JCAR014 and where chimeric antigen receptor T-cell research is headed for patients with chronic lymphocytic leukemia.

Dr. Kambhampati Discusses Data from the 2018 ASH Annual Meeting in CLL

February 13th 2019

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses data from the 2018 ASH Annual Meeting in chronic lymphocytic leukemia (CLL).

Dr. Arora on the Use of Venetoclax in CLL

February 8th 2019

Shagun Arora, MD, assistant clinical professor at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the use of venetoclax (Venclexta) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Kahl on Frontline Therapy Selection in CLL

February 7th 2019

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses frontline therapy selection in chronic lymphocytic leukemia (CLL).

Dr. Kambhampati on Frontline Ibrutinib Plus Obinutuzumab in CLL

February 6th 2019

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the combination of frontline ibrutinib plus obinutuzumab for the treatment of patients with chronic lymphocytic leukemia.

FDA Approves Ibrutinib Plus Obinutuzumab in Frontline CLL/SLL

January 28th 2019

The FDA has approved the combination of ibrutinib and obinutuzumab for the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Duvelisib Provides CLL Patients With a Later Line of Therapy

January 24th 2019

Ian W. Flinn, MD, PhD, discusses the potential impact of duvelisib on patients with chronic lymphocytic leukemia.

Dr. Seymour Discusses Rationale for MURANO Study in CLL

January 22nd 2019

John F. Seymour, MBBS, PhD, clinical hematologist, associate director of Clinical Research, Peter MacCallum Centre, director of the integrated Haematology Department of the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, discusses the rationale for the MURANO study in patients with chronic lymphocytic leukemia.

Dr. Arora on Novel Therapies in CLL

January 18th 2019

Shagun Arora, MD, assistant clinical professor at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses novel therapies in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Hill on Resistance to BTK Inhibition in CLL

January 16th 2019

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses resistance to BTK inhibition in chronic lymphocytic leukemia (CLL).

Targeting BCL-2 in Hematologic Malignancies

January 11th 2019

Over the past 2 decades, considerable efforts have focused on the development of therapies that can restore apoptosis in malignant cells.

BCL-2: Mechanisms and Prevalence

January 10th 2019

The understanding of the BCL2 oncogene and the BCL-2 protein family have motivated the current advancements in cancer therapeutics that target different members of apoptotic regulatory networks.

The Future of AML Therapy: Cause for Optimism

January 8th 2019

IDH Inhibitors in AML Therapy

January 8th 2019

BTK/BCL2 Inhibitors & Other Novel Agents in CLL Therapy

January 8th 2019

Treatment Options for Relapsed/Refractory AML

January 8th 2019

Treatment Options for Relapsed/Refractory CLL

January 8th 2019